| 双环铂治疗肿瘤安全性的回顾性分析 |
| |
| 引用本文： | 吴云波1,' target='_blank'>2,张维强2,魏智民2,张国庆1,方 丽1,焦顺昌1. 双环铂治疗肿瘤安全性的回顾性分析[J]. 现代肿瘤医学, 2018, 0(15): 2444-2448. DOI: 10.3969/j.issn.1672-4992.2018.15.033 |
| |
| 作者姓名： | 吴云波1 ' target='_blank'>2 张维强2 魏智民2 张国庆1 方 丽1 焦顺昌1 |
| |
| 作者单位： | 1.解放军总医院肿瘤科，北京 100853;2.中央军委联合参谋部警卫局卫生保健处，北京 100017 |
| |
| 摘 要： | 目的:观察双环铂治疗肿瘤的安全性。方法:收集2006年到2016年期间在中国人民解放军总医院首次住院治疗且接受过双环铂治疗的肿瘤患者129例，其中符合本次入选标准可供分析的病例共计40例，进而对这40例病例进行分析。结果:本次分析涉及16种瘤种，在安全性方面，双环铂治疗肿瘤的不良事件主要等级为1/2级；与治疗前相比，接受双环铂治疗后，红细胞、血小板和血红蛋白指标水平下降存在显著差异（红细胞:t=-3.91，P<0.001；血小板:t=-3.81，P<0.001；血红蛋白:t=-3.61，P=0.001），其他指标不存在统计学差异。经单药治疗或联合治疗分层后，显示仅在接受联合治疗后，血小板和血红蛋白的水平下降存在显著差异（血小板:t=-3.93，P=0.002；血红蛋白:t=-3.62，P=0.004），总胆红素水平上升存在显著差异（t=2.35，P=0.038），血清肌酐水平下降存在显著差异（t=-2.85，P=0.016）。无论单药治疗或联合用药，红细胞下降均存在显著的统计学差异（P<0.05）。结论:双环铂单药治疗肿瘤比联合治疗肿瘤在安全性方面具有一定的优势，与文献报道的双环铂自身毒性较低结论一致。
|
| 关 键 词： | 双环铂 安全性 不良事件 |
Retrospective analysis of safety for Dicycloplatin therapy in the treatment of cancer |
| |
| Wu Yunbo1,' target='_blank'>2,Zhang Weiqiang2,Wei Zhimin2,Zhang Guoqing1,Fang Li1,Jiao Shunchang1. Retrospective analysis of safety for Dicycloplatin therapy in the treatment of cancer[J]. Journal of Modern Oncology, 2018, 0(15): 2444-2448. DOI: 10.3969/j.issn.1672-4992.2018.15.033 |
| |
| Authors: | Wu Yunbo1 ' target='_blank'>2 Zhang Weiqiang2 Wei Zhimin2 Zhang Guoqing1 Fang Li1 Jiao Shunchang1 |
| |
| Affiliation: | 1.Department of Oncology，General Hospital of Chinese People's Liberation Army，Beijing 100853，China；2.Health Division of Guard Bureau，Joint Staff of the Central Military Commission of Chinese PLA，Beijing 100017，China. |
| |
| Abstract: | Objective:To report our clinical experience with patients receiving Dicycloplatin therapy on safety in the treatment of cancer.Methods:We reviewed the medical records of patients with cancer who first received treatment with Dicycloplatin therapy for all kinds of cancer from 2006 to 2016 in Chinese PLA General Hospital；and we analyzed available data for those who satisfied the inclusion criteria (40 patients in total).Results:In this study，16 kinds of tumors were included，and in terms of safety，the grade of adverse events of Dicycloplatin therapy were mainly classified to grade 1 or grade 2.After Dicycloplatin therapy，the level of erythrocyte，platelet and hemoglobin decreased significantly (erythrocyte:t=-3.91，P<0.001，platelet:t=-3.81，P<0.001，hemoglobin:t=-3.61，P=0.001).After stratified by Dicycloplatin monotherapy or joint therapy，the level of platelet and hemoglobin decreased significantly (platelet:t=-3.93，P=0.002，hemoglobin:t =-3.62，P=0.004)，the level of total bilirubin increased significantly(t=2.35，P=0.038)，the level of serum creatinine decreased significantly(t=-2.85，P=0.016).Conclusion:Dicycloplatin monotherapy showed certain advantages over joint therapy in terms of safety，which was consistent with those reported in the literature that the toxicity associated with Dicycloplatin therapy was relatively low. |
| |
| Keywords: | Dicycloplatin safety adverse event |
|
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
|
点击此处可从《现代肿瘤医学》下载免费的PDF全文 |
